Suppr超能文献

新型治疗方式对肝细胞癌患者生存率的影响。

The impact of newer treatment modalities on survival in patients with hepatocellular carcinoma.

作者信息

Taura Naota, Hamasaki Keisuke, Nakao Kazuhiko, Ichikawa Tatsuki, Nishimura Daisuke, Goto Takashi, Fukuta Mariko, Kawashimo Hiroshi, Fujimoto Masumi, Kusumoto Koichiro, Motoyoshi Yasuhide, Shibata Hidetaka, Eguchi Katsumi

机构信息

First Department of Internal Medicine, Nagasaki University School of Medicine, Sakamoto, Nagasaki, Japan.

出版信息

Clin Gastroenterol Hepatol. 2006 Sep;4(9):1177-83. doi: 10.1016/j.cgh.2006.06.008. Epub 2006 Aug 8.

Abstract

BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. However, although the therapeutic approaches for HCC have progressed rapidly, it remains unknown whether the current management of patients with HCC has reduced its mortality. We analyzed changes of survival rate in patients with HCC over a 20-year period.

METHODS

Between 1982 and 2001, 463 patients were diagnosed with HCC at our hospital. Subjects were enrolled in the current cohort according to the following inclusion criteria: HCC lesion measuring less than 3 cm in diameter, no evidence of extrahepatic metastasis, and no evidence of main portal vein infiltration/thrombosis. A total of 257 patients with HCC were recruited for this study, and categorized into 5-year intervals.

RESULTS

The survival rates improved significantly during the study period. When the patients were stratified according to Child-Pugh score, only patients with Child's B showed improved survival rates. Furthermore, patients with surgical resection or transarterial chemoembolization during the latter period had a better prognosis than those during the early period.

CONCLUSIONS

Our findings suggest that the development of therapeutic interventions for HCC have led to improvements in the prognosis for HCC patients.

摘要

背景与目的

肝细胞癌(HCC)是全球最常见的癌症之一。然而,尽管HCC的治疗方法发展迅速,但目前HCC患者的管理是否降低了其死亡率仍不清楚。我们分析了20年间HCC患者生存率的变化。

方法

1982年至2001年间,我院有463例患者被诊断为HCC。根据以下纳入标准将受试者纳入当前队列:HCC病变直径小于3 cm,无肝外转移证据,无主门静脉浸润/血栓形成证据。本研究共招募了257例HCC患者,并按5年间隔进行分类。

结果

在研究期间,生存率显著提高。当根据Child-Pugh评分对患者进行分层时,只有Child B级患者的生存率有所提高。此外,后期接受手术切除或经动脉化疗栓塞的患者预后优于早期患者。

结论

我们的研究结果表明,HCC治疗干预措施的发展已使HCC患者的预后得到改善。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验